Published on in Vol 7, No 10 (2020): October

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/21814, first published .
Digital Phenotyping to Enhance Substance Use Treatment During the COVID-19 Pandemic

Digital Phenotyping to Enhance Substance Use Treatment During the COVID-19 Pandemic

Digital Phenotyping to Enhance Substance Use Treatment During the COVID-19 Pandemic

Authors of this article:

Michael Hsu1 Author Orcid Image ;   David K Ahern2 Author Orcid Image ;   Joji Suzuki3 Author Orcid Image

Journals

  1. Nguyen T, Buxton J. Pathways between COVID-19 public health responses and increasing overdose risks: A rapid review and conceptual framework. International Journal of Drug Policy 2021;93:103236 View
  2. Perra N. Non-pharmaceutical interventions during the COVID-19 pandemic: A review. Physics Reports 2021;913:1 View
  3. Martinez-Martin N, Greely H, Cho M. Ethical Development of Digital Phenotyping Tools for Mental Health Applications: Delphi Study. JMIR mHealth and uHealth 2021;9(7):e27343 View
  4. Liu S, Heinzel S, Dolan R. Digital Phenotyping and Mobile Sensing in Addiction Psychiatry. Pharmacopsychiatry 2021;54(06):287 View
  5. Currey D, Torous J. Digital Phenotyping Data to Predict Symptom Improvement and Mental Health App Personalization in College Students: Prospective Validation of a Predictive Model. Journal of Medical Internet Research 2023;25:e39258 View
  6. Mosher Henke R. Knowing Well, Being Well: well-being born of understanding: Shifts in Health Behaviors Amid the COVID-19 Pandemic. American Journal of Health Promotion 2021;35(8):1162 View
  7. Marsch L, Chen C, Adams S, Asyyed A, Does M, Hassanpour S, Hichborn E, Jackson-Morris M, Jacobson N, Jones H, Kotz D, Lambert-Harris C, Li Z, McLeman B, Mishra V, Stanger C, Subramaniam G, Wu W, Campbell C. The Feasibility and Utility of Harnessing Digital Health to Understand Clinical Trajectories in Medication Treatment for Opioid Use Disorder: D-TECT Study Design and Methodological Considerations. Frontiers in Psychiatry 2022;13 View
  8. Hesse B, Kwasnicka D, Ahern D. Emerging digital technologies in cancer treatment, prevention, and control. Translational Behavioral Medicine 2021;11(11):2009 View
  9. Hsu M, Martin B, Ahmed S, Torous J, Suzuki J. Smartphone Ownership, Smartphone Utilization, and Interest in Using Mental Health Apps to Address Substance Use Disorders: Literature Review and Cross-sectional Survey Study Across Two Sites. JMIR Formative Research 2022;6(7):e38684 View
  10. Rosenthal A, Ebrahimi C, Wedemeyer F, Romanczuk-Seiferth N, Beck A. The Treatment of Substance Use Disorders: Recent Developments and New Perspectives. Neuropsychobiology 2022;81(5):451 View
  11. Engelmann L. Digital epidemiology, deep phenotyping and the enduring fantasy of pathological omniscience. Big Data & Society 2022;9(1):205395172110664 View
  12. Kane H, Gourret Baumgart J, El-Hage W, Deloyer J, Maes C, Lebas M, Marazziti D, Thome J, Fond-Harmant L, Denis F. Opportunities and Challenges for Professionals in Psychiatry and Mental Health Care Using Digital Technologies During the COVID-19 Pandemic: Systematic Review. JMIR Human Factors 2022;9(1):e30359 View
  13. Satre D, Meacham M, Asarnow L, Fisher W, Fortuna L, Iturralde E. Opportunities to Integrate Mobile App–Based Interventions Into Mental Health and Substance Use Disorder Treatment Services in the Wake of COVID-19. American Journal of Health Promotion 2021;35(8):1178 View
  14. Wu X, Du J, Jiang H, Zhao M. Application of Digital Medicine in Addiction. Journal of Shanghai Jiaotong University (Science) 2022;27(2):144 View
  15. Hesse B, Aronoff‐Spencer E, Ahern D, Mullett T, Gibbons C, Chih M, Hubenko A, Koop B. “Don't drop the patient:” Health information in a postpandemic world. World Medical & Health Policy 2022;14(2):310 View
  16. Lombardi A, Arya R, Rosen J, Thompson E, Welwean R, Tardif J, Rich J, Park J. Overdose Detection Technologies to Reduce Solitary Overdose Deaths: A Literature Review. International Journal of Environmental Research and Public Health 2023;20(2):1230 View
  17. Joyce C, Markossian T, Nikolaides J, Ramsey E, Thompson H, Rojas J, Sharma B, Dligach D, Oguss M, Cooper R, Afshar M. The Evaluation of a Clinical Decision Support Tool Using Natural Language Processing to Screen Hospitalized Adults for Unhealthy Substance Use: Protocol for a Quasi-Experimental Design. JMIR Research Protocols 2022;11(12):e42971 View
  18. Charron E, White A, Carlston K, Abdullah W, Baylis J, Pierce S, Businelle M, Gordon A, Krans E, Smid M, Cochran G. Prospective acceptability of digital phenotyping among pregnant and parenting people with opioid use disorder: A multisite qualitative study. Frontiers in Psychiatry 2023;14 View
  19. Loverock A, Marshall T, Viste D, Safi F, Rioux W, Sedaghat N, Kennedy M, Ghosh S. Electronic harm reduction interventions for drug overdose monitoring and prevention: A scoping review. Drug and Alcohol Dependence 2023;250:110878 View
  20. Campbell C, Chen C, Adams S, Asyyed A, Athale N, Does M, Hassanpour S, Hichborn E, Jackson-Morris M, Jacobson N, Jones H, Kotz D, Lambert-Harris C, Li Z, McLeman B, Mishra V, Stanger C, Subramaniam G, Wu W, Zegers C, Marsch L. Patient Engagement in a Multimodal Digital Phenotyping Study of Opioid Use Disorder. Journal of Medical Internet Research 2023;25:e45556 View
  21. Hsu M, Jung O, Kwan L, Jegede O, Martin B, Malhotra A, Suzuki J. Access challenges to opioid use disorder treatment among individuals experiencing homelessness: Voices from the streets. Journal of Substance Use and Addiction Treatment 2024;157:209216 View

Books/Policy Documents

  1. Shapira B, Neumark Y. Handbook of Substance Misuse and Addictions. View
  2. Shapira B, Neumark Y. Handbook of Substance Misuse and Addictions. View
  3. Berhe O, Gerhardt S, Schmahl C. Neuroscience of Social Stress. View
  4. De Lanerolle G, Phiri P, Haroon A. Clinical Trials and Tribulations. View
  5. Rigatti M, Carreiro S, Boyer E. Artificial Intelligence in Clinical Practice. View
  6. Volpe U, Elkholy H, Gargot T, Pinto da Costa M, Orsolini L. Tasman’s Psychiatry. View